Airfinity launches new Surplus Doses Analysis Tool

Posted on Jul 23, 2021

The surplus doses tool calculates the potential number of doses remaining from a country's purchase agreements, once they have vaccinated their populations, with the option of including boosters and alternative scenarios in the analysis. We can then see what these surpluses will be at the end of 2021 and 2022.

These surpluses can be further split amongst a country’s supplied vaccines, to get an idea of which specific vaccines a country might have a surplus of. The tool provides several scenarios to the user, all of which can be combined:

  1. Specify the age range of individuals receiving doses

  2. Specify the percentage of the specified population required to be vaccinated before doses are determined to be “surplus”

  3. Booster shots can be allowed for before we consider subsequent supply as surplus

  4. Hypothetical donations can be taken into account

  5. Expiration dates for vaccines can also be taken into account

Book a free walkthrough with our analysts and find out how the tool can benefit your team and strategic efforts.

More Insights From Airfinity

Introducing Airfinity Biorisk: Risk Surveillance and Analytics for 160+ Infectious Diseases

Oct 10, 2022

18 million monkeypox vaccines needed to protect most at risk, 85 million to protect wider gay community and health workers

Aug 25, 2022

Sales of COVID-19 antiviral pill Paxlovid to leap frog Merck’s competitor Molnupiravir

Jul 25, 2022

COVID-19 vaccines sales to bounce back with new jabs taking a fifth of the 2022 market

Jul 15, 2022

AstraZeneca and Pfizer/BioNTech saved over 12 million lives in the first year of vaccination

Jul 13, 2022

Global wastage of COVID-19 vaccines could be 1.1 billion doses

Jul 11, 2022